Login to Your Account

FDA draft: 'P' scores for endpoint component may be deemed misleading

By Mark McCarty
Regulatory Editor

Wednesday, January 18, 2017

The FDA has released a draft guidance for communications regarding on-label use of drugs and devices, which seems motivated in part by an interest in lending clarity to the off-label discussion.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription